Celcuity Stock Quote CELC - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

18.73

Bid

16.51

Ask

19.65

Volume

575,360

18.60 Day's Range 19.77

8.389 52 Week Range 22.188

Market Cap

584.939M

Previous Close

19.15

Open

19.41

Last Trade

199168

18.73

(priorref)

Last Trade Time

Financial Volume

$ 10,868,811

VWAP

18.8905

Average Volume (3m)

321,336

Shares Outstanding

31,230,085

Dividend Yield

PE Ratio

-9.18

Earnings Per Share (EPS)

-2.04

Revenue

Net Profit

-63.78M

Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered ... Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Show more

Sector

Medical Laboratories

Industry

Medical Laboratories

Website

www.celcuity.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Celcuity Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker CELC. The last closing price for Celcuity was $19.15. Over the last year, Celcuity shares have traded in a share price range of $ 8.389 to $ 22.188.

Celcuity currently has 31,230,085 shares outstanding. The market capitalization of Celcuity is $598.06 million. Celcuity has a price to earnings ratio (PE ratio) of -9.18.

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

The Phase 3 clinical trial will evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1	5.64015792442	17.73	19.77	17.23	580143	18.41864567	CS
4	2.23	13.5151515152	16.5	19.77	16.09	406824	17.9163247	CS
12	0.9	5.04767246214	17.83	19.77	13.715	321336	16.68785429	CS
26	3.91	26.383265857	14.82	22.188	13.715	269991	17.04303324	CS
52	8.58	84.5320197044	10.15	22.188	8.389	179710	15.91392453	CS
156	-2.57	-12.0657276995	21.3	23.113	4.81	100043	13.96367275	CS
260	-2.44	-11.5257439773	21.17	33.01	4.03	89283	16.41832293	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	260.07k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.61M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M